Statistics from Altmetric.com
In her narrative review,1 Maryanne Demasi highlighted how an aggressive focus on lowering low-density lipoprotein-cholesterol (LDL-c), a surrogate endpoint of coronary heart disease, together with a lack of transparency surrounding the raw data on statins, has led to the overprescription of statin drugs to healthy people at low cardiovascular risk. We fully agree and wish to shed further light on the cholesterol-statin controversy.
The multifunctional importance of cholesterol for every cell in the body cannot be forgotten. It is indeed incongruous to suggest that in every individual it is …
Contributors Both authors meet the criteria for authorship. The manuscript has been read and approved by both authors.
Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.